company background image
1795 logo

Lotus Pharmaceutical TWSE:1795 Stock Report

Last Price

NT$306.00

Market Cap

NT$80.9b

7D

11.5%

1Y

18.8%

Updated

28 Mar, 2024

Data

Company Financials +

Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$80.9b

1795 Stock Overview

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.

1795 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance4/6
Financial Health3/6
Dividends1/6

Lotus Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lotus Pharmaceutical
Historical stock prices
Current Share PriceNT$306.00
52 Week HighNT$349.50
52 Week LowNT$205.00
Beta0.50
1 Month Change3.38%
3 Month Change12.50%
1 Year Change18.83%
3 Year Change293.32%
5 Year Change155.00%
Change since IPO147.77%

Recent News & Updates

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Recent updates

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Shareholder Returns

1795TW PharmaceuticalsTW Market
7D11.5%3.2%1.9%
1Y18.8%5.3%26.7%

Return vs Industry: 1795 exceeded the TW Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: 1795 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 1795's price volatile compared to industry and market?
1795 volatility
1795 Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 1795 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1795's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1966n/aPetar Vazharovhttps://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products.

Lotus Pharmaceutical Co., Ltd. Fundamentals Summary

How do Lotus Pharmaceutical's earnings and revenue compare to its market cap?
1795 fundamental statistics
Market capNT$80.93b
Earnings (TTM)NT$4.11b
Revenue (TTM)NT$16.96b

19.7x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1795 income statement (TTM)
RevenueNT$16.96b
Cost of RevenueNT$7.57b
Gross ProfitNT$9.38b
Other ExpensesNT$5.28b
EarningsNT$4.11b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)15.52
Gross Margin55.34%
Net Profit Margin24.21%
Debt/Equity Ratio65.4%

How did 1795 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

23%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.